Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches
- 1 October 2007
- journal article
- Published by Microbiology Society in Journal of General Virology
- Vol. 88 (10) , 2719-2723
- https://doi.org/10.1099/vir.0.82753-0
Abstract
Chimeric 101F (ch101F) is a mouse–human chimeric anti-human respiratory syncytial virus (HRSV) neutralizing antibody that recognizes residues within antigenic site IV, V, VI of the fusion (F) glycoprotein. The binding of ch101F to a series of peptides overlapping aa 422–438 spanning antigenic site IV, V, VI was analysed. Residues 423–436 comprise the minimal peptide sequence for ch101F binding. Substitution analysis revealed that R429 and K433 are critical for ch101F binding, whilst K427 makes a minor contribution. Binding of ch101F to a series of single mutations at positions 427, 429 and 433 in the F protein expressed recombinantly on the cell surface confirmed the peptide results. Sequence analysis of viruses selected for resistance to neutralization by ch101F indicated that a single change (K433T) in the F protein allowed ch101F escape. The results confirm that ch101F and palivizumab have different epitope specificity and define key residues for ch101F recognition.Keywords
This publication has 31 references indexed in Scilit:
- Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its functionVirology Journal, 2006
- Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F proteinVirology Journal, 2005
- Respiratory Syncytial Virus Pneumonitis in Immunocompromised Adults: Clinical Features and OutcomeRespiration, 2005
- Surveillance of Clinical Isolates of Respiratory Syncytial Virus for Palivizumab (Synagis)–Resistant MutantsThe Journal of Infectious Diseases, 2004
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Respiratory Syncytial Virus Pneumonia among the Elderly: An Assessment of Disease BurdenThe Journal of Infectious Diseases, 1999
- Monoclonal Antibody-Resistant Mutants Selected with a Respiratory Syncytial Virus-Neutralizing Human Antibody Fab Fragment (Fab 19) Define a Unique Epitope on the Fusion (F) GlycoproteinVirology, 1998
- Respiratory Syncytial Virus Is an Important Cause of Community-Acquired Lower Respiratory Infection among Hospitalized AdultsThe Journal of Infectious Diseases, 1996
- Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virusJournal of General Virology, 1992
- Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virusJournal of General Virology, 1991